NASDAQ$TPST
Tempest Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for the year ended December 31, 2022 and provided a corporate update.
Tempest Therapeutics reported a net loss of $35.7 million for the year ended December 31, 2022. The company ended the year with $31.2 million in cash and cash equivalents.
- TPST-1120 randomized combination study in first-line HCC patients with partner Roche is fully enrolled, with initial data expected in the first half of 2023
- New data on TPST-1120 biomarker and proprietary small molecule TREX1 inhibitor accepted for presentation at AACR 2023
- TPST-1495 Phase 1 monotherapy and combination dose escalation and optimization ongoing, with initial data release planned by mid 2023
- Ended the year with $31.2 million in cash and cash equivalents
Headline financials
Revenue & EPS history
Tempest · Revenue · Quarterly
$0
Forward guidance
Based on current cash position and operating plan, Tempest expects to have sufficient resources to fund operations through the second quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-2.1%
Avg return
Earnings day
-3.1%
Avg return
5 days after
-10.2%
Avg return
30 days after
34%
12 / 35 earnings
Positive
+15.8%
Q2 2022
Best reaction
-41.3%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.2% | +4.5% | -36.2% | |
| Q3 2025 | -3.2% | -3.3% | -68.6% | |
| Q2 2025 | +10.0% | +31.5% | +33.7% | |
| Q1 2025 | -2.6% | -8.2% | +0.7% | |
| Q4 2024 | +5.9% | -9.5% | -28.9% | |
| Q3 2024 | -11.5% | -19.1% | -24.1% | |
| Q2 2024 | -16.8% | -21.4% | -11.4% | |
| Q1 2024 | -5.5% | -2.0% | -10.4% | |
| Q4 2023 | -3.1% | -5.9% | -18.1% | |
| Q3 2023 | +6.1% | +11.7% | +3.6% | |
| Q2 2023 | +7.2% | +13.5% | -29.1% | |
| Q1 2023 | +3.4% | +6.3% | -42.0% | |
| Q4 2022 | +10.2% | +8.1% | +80.3% | |
| Q3 2022 | -12.1% | -11.5% | -14.0% | |
| Q2 2022 | +15.8% | +18.2% | +5.1% | |
| Q1 2022 | +5.9% | +12.9% | -2.2% | |
| Q4 2021 | -3.6% | -18.8% | -12.4% | |
| Q3 2021 | -2.5% | -7.8% | -35.5% | |
| Q2 2021 | -0.1% | -6.3% | +6.3% | |
| Q1 2021 | -0.8% | -1.6% | -10.2% | |
| Q4 2020 | -41.3% | -41.7% | -46.3% | |
| Q3 2020 | -1.3% | -1.3% | +28.2% | |
| Q2 2020 | -2.6% | -3.6% | -17.7% | |
| Q1 2020 | -4.7% | +0.0% | +32.0% | |
| Q3 2019 | -2.7% | +1.2% | -21.1% | |
| Q2 2019 | -0.5% | -7.4% | -23.2% | |
| Q1 2019 | +2.6% | +0.9% | -21.2% | |
| Q3 2018 | -5.2% | -13.0% | -10.0% | |
| Q2 2018 | -14.4% | -8.9% | -15.6% | |
| Q1 2018 | +0.7% | +0.7% | -4.7% | |
| Q3 2017 | -4.6% | -2.9% | -0.7% | |
| Q2 2017 | +3.1% | -2.5% | -12.3% | |
| Q1 2017 | -0.4% | -1.8% | -8.1% | |
| Q3 2016 | -6.8% | -31.6% | -35.4% | |
| Q2 2016 | -0.5% | +11.2% | +12.7% | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro